ENP — Entropy Neurodynamics Share Price
0.000.00%
Last trade - 00:00- AU$48.92m
- AU$45.90m
- AU$1.59m
- 33
- 14
- 52
- 23
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 8.2 | ||
| Price to Tang. Book | 8.48 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 30.82 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -88.55% | ||
| Return on Equity | -92.06% | ||
| Operating Margin | -332.7% | ||
Financial Summary
| Year End 30th Jun | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 4.2 | 4.21 | 3.41 | 1.12 | 1.59 | n/a | n/a | -10.25% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Entropy Neurodynamics Limited, formerly Tryptamine Therapeutics Limited, is an Australia-based clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The Company’s lead program, TRP-8803, is a proprietary formulation of IV infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. The Company has completed a Phase 2a clinical trial for the treatment of binge eating disorder and for the treatment of fibromyalgia. Each of the studies is utilizing TRP-8802 (synthetic, oral psilocybin) to demonstrate clinical benefit in these indications.
Directors
- Jason Watson NEC
- Ian Dixon FDR
- Gregor Lichtfuss COO
- Chris Baldwin OTH
- Alison Cook OTH
- David Franks SEC
- Jennifer King DRC
- Elizabeth McGregor NED
- Last Annual
- June 30th, 2025
- Last Interim
- June 30th, 2025
- Incorporated
- May 15th, 2013
- Public Since
- December 18th, 2018
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 1,438,921,585
- Address
- Suite 201, 697 Burke Road, Camberwell, MELBOURNE, 3124
- Web
- https://tryptherapeutics.com/
- Phone
- +61 384190827
- Auditors
- William Buck Audit (Vic) Pty Ltd
Upcoming Events for ENP
Similar to ENP
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Entropy Neurodynamics share price?
As of Today at 01:29 UTC, shares in Entropy Neurodynamics are trading at AU$0.03. This share price information is delayed by 15 minutes.
How has the Entropy Neurodynamics share price performed this year?
Shares in Entropy Neurodynamics last closed at AU$0.03 and the price had moved by -19.05% over the past 365 days. In terms of relative price strength the Entropy Neurodynamics share price has underperformed the ASX All Ordinaries Index by -21.48% over the past year.
What are the analyst and broker recommendations for Entropy Neurodynamics?
The overall consensus recommendation for Entropy Neurodynamics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Entropy Neurodynamics dividend yield?
Entropy Neurodynamics does not currently pay a dividend.
Does Entropy Neurodynamics pay a dividend?
Entropy Neurodynamics does not currently pay a dividend.
When does Entropy Neurodynamics next pay dividends?
Entropy Neurodynamics does not currently pay a dividend.
How do I buy Entropy Neurodynamics shares?
To buy shares in Entropy Neurodynamics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Entropy Neurodynamics?
As of the previous close price of AU$0.03, shares in Entropy Neurodynamics had a market capitalisation of AU$48.92m.
Where are Entropy Neurodynamics shares listed?
Here are the trading details for Entropy Neurodynamics:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: ENP
What kind of share is Entropy Neurodynamics?
Based on an overall assessment of its quality, value and momentum Entropy Neurodynamics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Entropy Neurodynamics share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Entropy Neurodynamics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Entropy Neurodynamics. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +12.02%.
As of the last closing price of AU$0.03, shares in Entropy Neurodynamics were trading -0.67% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Entropy Neurodynamics PE Ratio?
The Entropy Neurodynamics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Entropy Neurodynamics?
Entropy Neurodynamics' management team is headed by:
- Jason Watson - NEC
- Ian Dixon - FDR
- Gregor Lichtfuss - COO
- Chris Baldwin - OTH
- Alison Cook - OTH
- David Franks - SEC
- Jennifer King - DRC
- Elizabeth McGregor - NED